×

Atara Bio to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will present at three upcoming investor conferences in June:

  • Goldman Sachs 37th Annual Global Healthcare Conference
    Tuesday, June 7, 2016, 8:00 a.m. PT
    Terranea Resort, Rancho Palos Verdes, CA

  • Jefferies 2016 Healthcare Conference
    Thursday, June 9, 2016, 2:30 p.m. ET
    The Grand Hyatt Hotel, New York, NY

  • JMP Securities 2016 Life Sciences Conference
    Tuesday, June 21, 2016, 4:00 p.m. ET
    The St. Regis New York Hotel, New York, NY

Live webcasts of the presentations will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. Archived replays of the webcasts will be available on the Company's website for 14 days following each presentation.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T cell product candidates and molecularly targeted product candidates. The T cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.


INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 sklass@burnsmc.com Media: Justin Jackson 212-213-0006 x327 jjackson@burnsmc.com

Source:Atara Biotherapeutics, Inc.